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Abstract
Aims/hypothesis The aim of this prospective nationwide study
was to examine antenatal pregnancy care and pregnancy out-
comes in women with type 1 and type 2 diabetes, and to
describe changes since 2002/2003.
Methods This national population-based cohort included
3036 pregnant women with diabetes from 155 maternity
clinics in England and Wales who delivered during 2015.
The main outcome measures were maternal glycaemic con-
trol, preterm delivery (before 37 weeks), infant large for ges-
tational age (LGA), and rates of congenital anomaly, stillbirth
and neonatal death.
Results Of 3036 women, 1563 (51%) had type 1, 1386 (46%)
had type 2 and 87 (3%) had other types of diabetes. The
percentage of women achieving HbA1c < 6.5% (48 mmol/
mol) in early pregnancy varied greatly between clinics (medi-
an [interquartile range] 14.3% [7.7–22.2] for type 1, 37.0%
[27.3–46.2] for type 2). The number of infants born preterm
(21.7% vs 39.7%) and LGA (23.9% vs 46.4%) were lower for
women with type 2 compared with type 1 diabetes (both
p < 0.001). The prevalence rates for congenital anomaly
(46.2/1000 births for type 1, 34.6/1000 births for type 2) and
neonatal death (8.1/1000 births for type 1, 11.4/1000 births for
type 2) were unchanged since 2002/2003. Stillbirth rates are
almost 2.5 times lower than in 2002/2003 (10.7 vs 25.8/1000
births for type 1, p = 0.0012; 10.5 vs 29.2/1000 births for type
2, p = 0.0091).
Conclusions/interpretation Stillbirth rates among women
with type 1 and type 2 diabetes have decreased since
2002/2003. Rates of preterm delivery and LGA infants are
lower in women with type 2 compared with type 1 diabetes.
In women with type 1 diabetes, suboptimal glucose control
and high rates of perinatal morbidity persist with substantial
variations between clinics.
Data availability Further details of the data collection meth-
odology, individual clinic data and the full audit reports for
healthcare professionals and service users are available from
http://content.digital.nhs.uk/npid.
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Introduction
Pregnancy in women with diabetes is associated with in-
creased risks of serious adverse outcomes with a two-to-five
fold increased risk of congenital anomaly, stillbirth and neo-
natal death compared with the general maternity population
[1–3]. Less severe but more frequent perinatal complications
relating to maternal diabetes include preterm delivery, large
for gestational age (LGA) infants and neonatal intensive care
unit admission, affecting approximately one in two babies [4,
5]. Nationwide studies from the Netherlands, Sweden and
Finland suggest no improvement in either rates of serious
adverse pregnancy outcomes or perinatal complications in re-
cent decades, with possible explanations including increasing
maternal age, longer duration of diabetes and increasing rates
of overweight and obesity among women of reproductive
years.
A 2002/2003 population-based study, conducted by the
Confidential Enquiry into Maternal and Child Health
(CEMACH), examined the quality of maternity care and doc-
umented pregnancy outcomes in the UK among women with
diabetes, concluding that pregnancy preparation was inade-
quate, resulting in potentially modifiable poor pregnancy out-
comes in both type 1 and type 2 diabetes [6]. Since then the
National Institute for Health and Care Excellence (NICE)
have developed diabetes pregnancy guidelines with a clear
emphasis on improving provision of prepregnancy and ante-
natal diabetes care [7]. The NICE guideline recommendations
for prepregnancy preparation include taking 5 mg preconcep-
tion folic acid, presenting for antenatal care before 8 weeks’
gestation and avoiding potentially harmful medications. The
2015 update lowered the maternal glycaemic control target
from HbA1c < 7.0% (53 mmol/mol) to HbA1c < 6.5%
(48 mmol/mol) and recommended elective delivery between
37+0 and 38+6 weeks’ gestation [8].
Responding to the NICE guidelines, a National Pregnancy
in Diabetes (NPID) audit was established to document the
pregnancy preparation, antenatal care and fetal health out-
comes for pregnant women with type 1 and type 2 diabetes
[9].
Here we present pregnancy outcomes of women with dia-
betes who delivered between 1 January 2015 and 31
December 2015. Our aims were to provide contemporary data
on the rates of serious adverse pregnancy outcomes (congen-
ital anomaly, stillbirth and neonatal death) and perinatal
complications (preterm delivery, LGA and neonatal care ad-
mission), and to explore the relationship between maternal
deprivation and clinic-to-clinic variations with maternal
glycaemic control and folic acid supplementation. We also
describe changes since the previous 2002/2003 CEMACH
survey.
Methods
Healthcare professionals at each maternity unit completed
standardised web-based data entry forms for every pregnant
woman with diabetes who delivered between 1 January and
31 December 2015. As not all pregnancies resulted in a deliv-
ery these numbers included pregnancies ending in miscarriage
or termination within this date range. All maternity units in
England, Wales and the Isle of Man providing antenatal dia-
betes care were expected to participate (http://digital.nhs.uk/
npid). Data were obtained only from women who provided
written informed consent. The information leaflet and consent
form met the Health Research Authority requirements for
clinical audit, and research ethics approval was not required.
Linkage with data collected in other systems (Hospital
Episodes Statistics data, Patient Episode Database for Wales,
National Diabetes Audit) allowed only a limited number of
data items to be collected by local teams. This included
information regarding type of diabetes, medications and
folic acid use before conception. Data regarding pregnancy
outcome was completed locally at 28 days after delivery,
miscarriage or termination.
We defined pregestational diabetes as diabetes that had
been diagnosed before pregnancy, and excluded women with
diabetes who presented during pregnancy. Women with
monogenic diabetes, or where there was doubt about whether
they had type 1 or type 2 diabetes, or the type of diabetes data
item was missing were classified as ‘other’ (these pregnancies
were excluded from analyses comparing type 1 and type 2
diabetes). Glycaemic control was derived from HbA1c mea-
surements, and the first and last recorded values during preg-
nancy were collected. HbA1c was measured locally using
DCCT-aligned assays. We explored the relationship between
maternal deprivation with glycaemic control and folic acid
supplementation using an index of multiple deprivation score
for women living in England and Wales where postcode de-
tails were recorded in the National Diabetes Audit [10]. For
data protection of potentially sensitive information in the
clinic-to-clinic comparisons, we included only clinics with at
least ten completed pregnancy records; therefore, 130 clinics
were included for type 1 diabetes and 103 clinics for type 2
diabetes comparisons.
We defined stillbirth as a fetal loss occurring after
24 weeks’ gestation, and neonatal death as death of a live
born infant up to 28 days after delivery. We collected data
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on congenital anomalies for live births and terminations
of pregnancy at any gestation, including for stillbirths and
for fetal loss after 20 weeks’ gestation. The reported diagnoses
for congenital anomaly were obtained from the hospital ICD-
10 codes (www.who.int/classifications/icd/en/).We calculated
the congenital anomaly rate as the number of infants with one
or more congenital anomalies divided by the number of live
births, terminations, stillbirths and fetal loss after 20 weeks’
gestation. Infant birthweight was adjusted for maternal
ethnicity, height and weight, infant sex, and gestational age
at delivery for singleton pregnancies using customised
centiles with large and extreme LGA defined as >90th and
>97.7th percentiles, respectively (GROW Centile Calculator
v5.7.7.1, Gestation Network, www.gestation.net) [11].
Variables which were not normally distributed are giv-
en as median (interquartile range [IQR]), while normally
distributed variables are given as mean (SD). Univariate
analyses comparing the proportions between groups were
performed using z tests and t tests for comparing contin-
uous variables. We used Stata 8.0 for analyses and
Poisson distribution to obtain 95% CIs for the rate and
prevalence ratios.
Results
Participation
During the 12 month study period, 155 National Health
Service (NHS) maternity clinics participated. Together they
contributed 3044 pregnancies among 3036 women with dia-
betes, providing data for 3086 pregnancies (eight women had
two pregnancies and 42 twin pregnancies were recorded). We
report infant health outcomes for 2866 pregnancies that con-
tinued beyond 24weeks’ gestation. Table 1 gives a description
of the numbers of women and pregnancies according to type
of diabetes.
Maternal characteristics
Almost half of the women included in the study (n = 1386;
46%) had type 2 diabetes, rising to more than 50% in large
metropolitan regions (London, West Midlands, Yorkshire and
Humber). Ninety per cent of Asian women and 71% of Black
women had type 2 diabetes. As expected, women with type 2
diabetes were significantly older (33.6 vs 29.9 years;
p < 0.001), had higher BMI (33.3 vs 26.8 kg/m2; p < 0.001),
had shorter diabetes duration (4.8 vs 14.9 years; p < 0.001)
and were more likely to live in the most deprived quintile of
deprivation (38.5% vs 20.9%; p < 0.001) than women with
type 1 diabetes (Table 2).
Prepregnancy preparation
Preconception folic acid Women with type 2 diabetes were
significantly less likely to take the recommended 5 mg dose of
folic acid before conception compared with women with type
1 (22.5% vs 46.1%; p < 0.001; Table 2). There was also
marked variation between clinics in the percentage of women
with type 2 diabetes taking 5 mg folic acid (Fig. 1d); 33% of
women attending the top quartile clinics took 5 mg folic acid
compared with 15% in the lowest quartile (21.3% [15.4–
33.2]). Over half the women with type 1 diabetes attending
the top quartile clinics took 5 mg folic acid compared with less
than a third in the lowest quartile clinics (42.9% [31.5–52.3];
Fig. 1b). Maternal deprivation was strongly associated with
folic acid use among women with type 1 diabetes, with 75.1%
use among women with type 1 diabetes living in the least
deprived areas (vs 37.5% in the most deprived areas;
p < 0.05, data not shown).
Table 1 Numbers of women,
pregnancies and infants registered
in the study during 2015
All Type 1 diabetes Type 2 diabetes Other
Women 3036 1563 1386 87
Pregnancies 3044 1566 1391 87
Total pregnancy outcomes 3086a 1587 1409 90
Pregnancies ongoing after 24 weeks 2866 1470 1313 83
Live births after 24 weeks 2868 1474 1313 81
Stillbirth 35 16 14 5
Infants born after 24 weeks 2903 1490 1327 86
Infants with unknown gestation 4 1 3 6
Live births before 24 weeks 1 1 0 0
Total registered births 2908 1492 1330 86
a Eight women had two pregnancies and 42 twin pregnancies were recorded among 3036 women, providing
outcome data for 3086 pregnancies
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Table 2 Maternal and neonatal
characteristics by diabetes type Type 1 diabetes
n = 1563 (53%)a
Type 2 diabetes
n = 1386 (47%)a
p value
Age at delivery (years) 29.9 (5.7) 33.6 (5.2) <0.001
Duration of diabetes (years) 14.9 (8.3) 4.8 (4.3) <0.001
BMI (kg/m2)b 26.8 (5.6) 33.3 (7.3) <0.001
BMI category
18.5–24.9 660 (42%) 159 (11%)
25–29.9 473 (30%) 264 (19%)
≥ 30 335 (21%) 885 (64%)
Ethnicity n = 1201 n = 884
White 883 (74%) 406 (46%) <0.05
Asian 27 (2%) 247 (28%)
Black 32 (3%) 79 (9%)
Mixed/other 43 (4%) 47 (5%)
Not stated/unknown 216 (18%) 105 (12%)
Deprivation quintile n = 1197 n = 880 <0.001
1: least deprived 17.5% 7.4%
2 18.6% 11.5%
3 21.7% 17.0%
4 21.3% 25.6%
5: most deprived 20.9% 38.5%
5 mg preconception folic acid 720 (46.1%) 312 (22.5%) <0.001
Booking before 8 weeks 850 (54.4%) 501 (36.2%) <0.001
Potentially harmful medications 45 (2.9%) 119 (8.6%) <0.001
Early pregnancy HbA1c n = 1306 n = 1024
% 7.6 (6.8–8.7) 6.8 (6.2–8.0) <0.001
mmol/mol 60.0 (51.0–72.0) 51.5 (44.0–64.3)
HbA1c < 6.5% (48 mmol/mol) 16.2% 38.3%
Late pregnancy HbA1c n = 1210 n = 1017
% 6.7 (6.1–7.5) 5.9 (5.5–6.5) <0.001
mmol/mol 50 (43–58) 41 (37–47)
HbA1c < 6.5% (48 mmol/mol) 40.0% 76.0%
Perinatal outcomesc,d
Gestational age at delivery (weeks) 36.4 (2.0) 37.1 (2.0) <0.001
Preterm delivery <37+0 weeks 568 (39.7%) 278 (21.7%) <0.05
LGA >90th percentile 667 (46.4%) 307 (23.9%) <0.05
LGA >97.7th percentile 423 (29.4%) 180 (14.0%)
Serious adverse pregnancy outcomed
Congenital anomaly 69 (46.2/1000) 46 (34.6/1000) NS
Stillbirth 16 (10.7/1000) 14 (10.5/1000) NS
Neonatal death 12 (8.1/1000) 15 (11.4/1000) NS
Data are presented as n (%), mean (SD), median (IQR) or n (n per 1000 births)
a 87 (3%) women had ‘other’ types of diabetes, these pregnancies were excluded from analyses comparing type 1
and type 2 diabetes
b The maternal BMI at booking was unknown for four women with type 1 and two women with type 2 diabetes
c The gestation age at delivery was available for 1433 infants of mothers with type 1 diabetes and for 1280 with
type 2 diabetes. The customised birthweight percentiles were calculated for 1438 infants of mothers with type 1
diabetes and for 1287 with type 2 diabetes
d The data presented for serious adverse pregnancy outcomes and perinatal complications include only singleton
infants
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Glycaemic control in early pregnancy
Although glycaemic control was suboptimal in both type 1
and type 2 diabetes, women with type 2 diabetes were more
than twice as likely to achieve target HbA1c levels of <6.5%
(48 mmol/mol) in early pregnancy (38.3% vs 16.2%;
p < 0.001; Table 2). Women achieving target HbA1c levels
had lower BMI at booking (25.7 vs 27.0 kg/m2 for type 1,
31.9 vs 34.0 kg/m2 for type 2; p < 0.001). Women with type 1
diabetes who achieved target HbA1c levels were older (31.3 vs
29.8 years; p < 0.001) and lived in the least deprived areas,
with almost one in four women in the least deprived areas
achieving target HbA1c compared with one in ten women in
the most deprived areas (24% vs 9.9%; p < 0.001). For women
with type 2 diabetes, only maternal BMI (31.9 vs 34.0) and
shorter diabetes duration (4.2 vs 5.4 years; both p < 0.001)
were associated with achieving target HbA1c levels (data not
shown). The percentage of women with type 1 and type 2
diabetes achieving target HbA1c levels in early pregnancy also
varied greatly between clinics (14.3% [7.7–22.2] for type 1
and 37.0% [27.3–46.2] for type 2; Fig. 1a, c). The top quartile
clinics had 22% of women with type 1 and 46% with type 2
diabetes achieving target HbA1c levels with 7% and 27%,
respectively, in the lowest quartile clinics.
Presenting for antenatal care prior to 8 weeks’ gestation
was more common in women with type 1 diabetes (54.4%
vs 36.2%; p < 0.001; Table 2), again with substantial variation
between clinics (55.0% [37.2–65.0] and 36.4% [21.7–50.0],
respectively). Periconception exposure to potentially harmful
medications, such as statins, ACE inhibitors or angiotensin
receptor blockers, was less common in women with type 1
compared with type 2 diabetes (2.9% vs 8.6%; p < 0.001).
Glycaemic control in late pregnancy
As expected, maternal HbA1c levels decreased during preg-
nancy. After 24 weeks’ gestation in women with type 2 diabe-
tes, 76.0% achieved target HbA1c levels <6.5% (48 mmol/
mol) (Table 2) and 85.9% achieved HbA1c < 7.0%
(53 mmol/mol) (Table 3). Only 40.0% and 59.5% of women
with type 1 diabetes achieved these targets, respectively
(p < 0.001).
Perinatal morbidity
Preterm delivery While the majority of live singleton births
were between 37+0 and 38+6 weeks (mean gestation 36.4 for
type 1 and 37.1 for type 2; p < 0.001), the rates for preterm
delivery before 37 weeks were 39.7% in women with type 1
and 21.7% in those with type 2 diabetes (p < 0.05; Table 2).
Among women with suboptimal early glycaemic control
(HbA1c level ≥ 6.5% [48 mmol/mol]) the preterm birth rate
was significantly lower if they later achieved HbA1c levels
<6.5% (48 mmol/mol) after 24 weeks’ gestation (30.4% vs
48.0% for type 1; 21.6% vs 35.7% for type 2, both
p < 0.001; Fig. 2a).
LGA The numbers of large and extreme LGA infants
(birthweight >90th and >97.7th percentiles, respectively) were
significantly higher for women with type 1 diabetes (46.4%
and 29.4% for type 1 vs 23.9% and 14.0% for type 2, respec-
tively; both p < 0.001; Table 2). As with preterm delivery, the
LGA rates were significantly lower among women with sub-
optimal early glucose control if they later achieved HbA1c
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Fig. 1 Variation between clinics
in the percentage of women
taking 5 mg folic acid and
achieving target HbA1c levels
<6.5% (48 mmol/mol) in early
pregnancy. Percentage of women
with type 1 diabetes: (a)
achieving target HbA1c levels in
early pregnancy and (b) taking
5 mg folic acid and at individual
clinics. Percentage of women
with type 2 diabetes: (c) achieving
target HbA1c levels in early
pregnancy and (d) taking 5 mg
folic acid at individual clinics.
The clinics are ranked from
smallest number to greatest
number of women achieving the
targets left to right. Solid line,
median; dashed lines, IQR
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levels <6.5% (48 mmol/mol) (34.2% vs 54.9% for type 1;
19.0% vs 47.4% for type 2, both p < 0.001; Fig. 2b).
Neonatal intensive care unit admission LGA infants were
more likely to be admitted for neonatal care than infants
appropriate for gestational age (32.1% vs 25.6% for type 1,
25.6% vs 11.4% for type 2; p < 0.05). Admission to neonatal
care units was reduced among term infants (i.e. born at or after
37+0 weeks’ gestation) of women with suboptimal glycaemic
control in early pregnancy if they later achieved HbA1c levels
Table 3 Comparisons between
the NPID 2015 and CEMACH
2002/2003 cohorts
NPID 2015 CEMACH 2002/2003
Number of women 3036 2359
Number of infants 2866 2400
Number of clinicsa 155 231
Pregnancies per clinic 19.6 10.2
Type 1 diabetesb 1563 (51%) 1707 (72%)
Type 2 diabetesb 1386 (46%) 652 (28%)
Maternal duration of diabetes (years)
Type 1 diabetes 14.9 13
Type 2 diabetes 4.8 3
Preconception folic acid (any dose)c
Type 1 diabetes 51.7% 42.9%
Type 2 diabetes 33.7% 29.4%
Maternal glycaemic control
Early pregnancy measurement <13 weeks 78% 67%
Type 1 diabetes
HbA1c % 7.6 (6.8–8.7) 7.5 (6.6–8.5)
HbA1c mmol/mol 60 (51–72) 58 (48–69)
HbA1c < 7% (53 mmol/mol) 29.4% 35.2%
Type 2 diabetes
HbA1c % 6.8 (6.2–8.0) 7.0 (6.1–8.1)
HbA1c mmol/mol 51 (44–64) 53 (43–65)
HbA1c < 7% (53 mmol/mol) 52.4% 49.0%
Late pregnancy >24 weeks
Type 1 diabetes
HbA1c % 6.7 (6.1–7.5) 6.6 (6.0–7.3)
HbA1c mmol/mol 50 (43–58) 49 (42–56)
HbA1c < 7% (53 mmol/mol) 59.5% 65.0%
Type 2 diabetes
HbA1c % 5.9 (5.5–6.5) 6.3 (5.7–6.9)
HbA1c mmol/mol 41 (37–47) 45 (39–52)
HbA1c < 7% (53 mmol/mol)
d 85.9% 75.4%
Severe adverse pregnancy outcomes
Congenital anomalye 117 109
Type 1 diabetes 69 (46.2/1000) 81 (48/1000)
Type 2 diabetes 46 (34.6/1000) 28 (43/1000)
Stillbirth 30 63
Type 1 diabetes 16 (10.7/1000) 44 (25.8/1000)
Type 2 diabetes 14 (10.5/1000) 19 (29.2/1000)
Neonatal death 27 22
Type 1 diabetes 12 (8.1/1000) 16 (9.6/1000)
Type 2 diabetes 15 (11.4/1000) 6 (9.5/1000)
Data are presented as n (%), median (IQR) or n (n per 1000 births)
a CEMACH included clinics from England, Wales and Northern Ireland, and informed consent was not obtained.
NDIP 2015 included clinics from England, Wales and the Isle of Man, and only collected data with written
informed consent
b 87 (3%) women with ‘other’ types of diabetes are included for comparison with CEMACH but were excluded
from subsequent analyses comparing type 1 and type 2 diabetes
c The proportion of women taking preconception folic acid (any dose) has increased significantly in type 1
(p < 0.001) and type 2 (p = 0.022) diabetes since 2002/2003
d The proportion of women with type 2 diabetes achieving HbA1c < 7% (53 mmol/mol) after 24 weeks has
increased significantly since 2002/2003 (p = 0.05)
e CEMACH included only major congenital anomaly, with 141 anomalies among 109 infants. NPID 2015
included major and minor anomalies identified based on the ICD-10 codes for congenital anomalies prior to
hospital discharge. There were 156 anomalies among 117 infants (69 for women with type 1, 46 for women with
type 2 and two for women with ‘other’ forms of diabetes)
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<6.5% (48 mmol/mol) (22.7% vs 33.4% for type 1 and 12.2%
vs 23.6% for type 2; p < 0.05).
Comparisons with the 2002/2003 CEMACH data
Maternal and demographic characteristics This cohort was
larger than the previous CEMACH survey, with 685 more
diabetes pregnancies and a striking increase in the proportion
of pregnancies complicated by type 2 diabetes (Table 3).
There was also more concentrated data focusing on pregnancy
care across fewer clinics, with 3044 diabetes pregnancies
across 155 maternity clinics (19.6 per clinic) in 2015, com-
pared with 2359 diabetes pregnancies in 231 clinics (10.2 per
clinic) in 2002/2003. The duration of diabetes was longer (by
approximately 2 years) in both type 1 and type 2 diabetes.
More women were taking folic acid supplementation before
conception and more had a recorded first trimester measure-
ment of HbA1c. There was no improvement in glucose control
in type 1 diabetes but some improvement during late gestation
in type 2 diabetes, with an increased proportion of women
who achieved HbA1c < 7.0% (53 mmol/mol) after 24 weeks
in 2015 (85.9% vs 75.4%; p < 0.05).
Serious adverse pregnancy outcomes In 2015, the stillbirth
rate was high (10.7/1000 for type 1 and 10.5/1000 for type 2;
Table 3) compared with the general maternity population rate
of 4.7/1000 [12]. However, it was almost 2.5-fold lower than
in 2002/2003 (Fig. 3). The neonatal death rate was also high
(8.1/1000 for type 1 and 11.4/1000 for type 2 diabetes), but
unchanged compared with 2002/2003. The prevalence of con-
genital anomalies (including all major and minor anomalies
detected at hospital discharge) was 46.2/1000 for type 1 and
34.6/1000 for type 2 diabetes (Table 3). These data are not
directly comparable with the 2002/2003 data, which included
only major congenital anomalies.
Discussion
This large national study details the pregnancy outcomes of
women with diabetes more than a decade after the 2002/2003
CEMACH survey. While the pregnancy outcomes of women
with diabetes were still suboptimal compared with the general
maternity population, substantial progress has beenmade with
significant reductions in stillbirths in both type 1 and type 2
diabetes. There were fewer preterm deliveries, LGA infants
and neonatal care unit admissions in women with type 2 com-
pared with type 1 diabetes, reflecting the better antenatal
glycaemic control in type 2 diabetes. Glucose control in wom-
en with type 1 diabetes was suboptimal, with persistently high
rates of preterm delivery, LGA and neonatal care unit admis-
sions. The highest rates of neonatal complications were seen
in women with HbA1c levels ≥6.5% (48 mmol/mol) after
24 weeks’ gestation.
Over the past decade the proportion of pregnant women
with type 2 diabetes has risen from 28% to 46% of all diabetes
pregnancies, with type 2 now outnumbering type 1 diabetes
pregnancies in some metropolitan areas. The proportion of
women taking preconception folic acid supplementation has
increased both in type 1 and type 2 diabetes, which is in
contrast to some recent data suggesting a small decline (from
35% to 31%) in the general maternity population [13].
Our data demonstrate the ongoing healthcare inequalities
between women with type 1 and type 2 diabetes and the strik-
ing contribution of maternal deprivation in type 1 diabetes. In
women with type 1 diabetes, 75% of those living in the most
socioeconomically advantaged areas took 5 mg preconception
folic acid and 25% achieved target HbA1c levels in early preg-
nancy, whereas only 37% of women living in the most disad-
vantaged areas took folic acid and only 10% achieved target
HbA1c levels in early pregnancy. This information highlights
26.4
30.4
48.0
16.2
21.6
35.7
0
25
50
P
er
ce
nt
ag
e 
of
 b
irt
hs
At target HbA1c
at 13 and 24 weeks
Above target <13 weeks;
at target HbA1c >24 weeks
Above target HbA1c
at 13 and 24 weeks
a
b
26.8
34.2
54.9
14.6
19.0
47.4
0
20
40
60
P
er
ce
nt
ag
e 
of
 in
fa
nt
s
At target HbA1c
at 13 and 24 weeks
Above target <13 weeks;
at target HbA1c >24 weeks
Above target HbA1c
at 13 and 24 weeks 
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the need to more effectively target prepregnancy care to wom-
en living in deprived areas. Previous studies have shown that
targeting all women of reproductive years can minimise the
impact of maternal deprivation on prepregnancy care atten-
dance, folic acid supplementation and early pregnancy
glycaemic control [14].
It is disappointing that so few women with type 1 diabetes
achieved the NICE recommended glycaemic control target for
HbA1c in early and late pregnancy (16.1% and 40.0% respec-
tively). We speculate that this is due to previously described
physiological and pharmacological challenges of matching
pre-meal insulin boluses to postprandial glucose profiles in
early and late gestation [15, 16]. We have shown that while
women achieving target glycaemic control are older, leaner
and more socially advantaged, there is substantial variation
across clinics, suggesting that the impact of clinic context is
also important. Further work is needed to understand whether
these clinic-to-clinic variations relate to clinic size and/or staff
experience of implementing newer technologies such as insu-
lin pump therapy and continuous glucose monitoring before
and during pregnancy.
While there is much emphasis on improving preconception
and first trimester glucose control to reduce congenital anom-
aly, stillbirth and neonatal death, our data also indicate the
importance of optimal glucose control in late gestation for
reducing the rates of preterm delivery, LGA infants and neo-
natal intensive care unit admission. An important take home
message for women with unplanned pregnancy and/or subop-
timal early glucose control is that achieving HbA1c < 6.5%
(48 mmol/mol) after 24 weeks was very effective for reducing
perinatal complications both in type 1 and type 2 diabetes.
The absolute risk of stillbirth has consistently remained 10–
13/1000 over three diabetes pregnancy audit years, which now
includes 6675 diabetes pregnancies [17]. Recent data from
Sweden have comparable absolute stillbirth rates (15/1000)
among women with type 1 diabetes [1]. However, the
Swedish diabetes rates are still five times higher than the
low background maternity population rates (3/1000) charac-
teristic of high-income countries. In 2002/2003 there was a
similar fivefold increase in stillbirths among women with di-
abetes in the UK [3].
The reductions in stillbirths in type 1 and type 2 diabetes
are not solely due to improvements in the general maternity
population [12], as the UK currently reports one of the slowest
rates of decline in stillbirth of approximately 17% (from 5.3 to
4.4/1000 births) over the past decade [18]. Although there are
clear maternal risk factors, including previous stillbirth, mul-
tiple pregnancy, nulliparity, diabetes, maternal age over
40 years, non-White ethnicity, smoking and obesity, most of
the variability in stillbirth rates is independent of established
risk factors [19, 20]. We can only speculate as to the possible
explanations for recent improvements, which may include
earlier elective birth recommendations (37+0 weeks’ gestation),
tighter glycaemic control targets (HbA1c < 6.5% or 48 mmol/
mol) and/or greater concentrations of women with diabetes
among fewer maternity clinics.
Stillbirth is the most common cause of perinatal death [21],
so it is surprising that the reduction in stillbirths was not ac-
companied by a reduction in the neonatal death rate (8.1 vs
9.6/1000 for type 1 and 11.4 vs 9.5/1000 for type 2) since
2002/2003. The reasons for this are unknown and will require
further evaluation in larger datasets over longer time frames.
Our study is one of the largest to describe the pregnancy
outcomes associated with contemporary diabetes care and in-
cludes over 3000 women with pregnancies complicated by
diabetes. Our large sample size provides the statistical power
for evaluating trends in serious but rare outcomes. Other large-
scale studies conducted over 10–20 years in Sweden [1] and
Finland [5] are less relevant to current clinical practice, and in
particular to the increasing problem of type 2 diabetes in preg-
nancy [22]. Our cohort is larger than any previous studies of
pregnant women with type 2 diabetes and confirms meta-
analyses findings that there are no differences in the rates of
congenital anomalies, stillbirths and perinatal deaths between
type 1 and type 2 diabetes [23]. We do confirm important
differences in the perinatal outcomes of type 1 and type 2
diabetes pregnancy with significantly lower rates of preterm
delivery, LGA infants and neonatal intensive care unit admis-
sions in type 2 diabetes.
Our study should be interpreted in the context of poten-
tial limitations. First, these are cross-sectional analyses,
which preclude us from making causal inferences. Second,
use of routinely collected data means we have little control
over errors during data collection and variations due to dif-
ferences in timing and laboratory methods for HbA1c levels.
Third, because of the information governance requirements
and the pre-specified nature of these analyses, we are unable to
analyse whether there are significant, independent effects of
HbA1c in early and late pregnancy and/or maternal BMI on
neonatal outcomes. Furthermore, we cannot guarantee that
data from all women and all maternity clinics are included,
and we lack information for women who did not provide
consent. The numbers of women who refuse consent is an-
ecdotally very small. For 94 clinics that responded to an
electronic survey, an average of one woman per clinic was
unable to and/or refused consent (C. Cartwright, P. Curnow,
C. Sylvester, B. Young, unpublished data). Having 3044
pregnancies in women providing consent is at least compa-
rable to the 2359 pregnancies without consent in
2002/2003. We also cannot be certain that the 87 women
where the type of diabetes is classified as ‘unknown’ did not
have type 1 or type 2 diabetes.
More work is needed to ensure that women with type 2
diabetes and their community healthcare providers are aware
of the importance of safe effective contraception and/or
prepregnancy care. Further research is needed to better
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understand the impact of clinic size and whether centralisation
in fewer, larger clinics would improve glucose control and
pregnancy outcomes. It remains to be seen whether recent
advances in continuous glucose monitoring and closed-loop
insulin delivery will be effective for improving late gestation
glucose control and reducing perinatal morbidity in type 1
diabetes pregnancy [24, 25]. For stillbirth, research to identify
better predictors of placental dysfunction such as erythropoi-
etin, pregnancy associated plasma protein A, alpha fetoprotein
and angiogenic/antiangiogenic factors in women with diabe-
tes is needed [26–28].
The NPID data provides information that can be used at
the level of individual maternity clinics so service users,
healthcare professionals and funders can make informed
healthcare choices. It has demonstrated substantial nation-
wide progress in diabetes stillbirth reductions but highlights
ongoing challenges to consistently improve glucose control
and reduce perinatal complications in type 1 diabetes
pregnancy.
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